JP6210640B2 - ホリナートカルシウム含有錠 - Google Patents
ホリナートカルシウム含有錠 Download PDFInfo
- Publication number
- JP6210640B2 JP6210640B2 JP2014126338A JP2014126338A JP6210640B2 JP 6210640 B2 JP6210640 B2 JP 6210640B2 JP 2014126338 A JP2014126338 A JP 2014126338A JP 2014126338 A JP2014126338 A JP 2014126338A JP 6210640 B2 JP6210640 B2 JP 6210640B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- calcium
- folinate
- present
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 3
- 239000011575 calcium Substances 0.000 title description 3
- 229910052791 calcium Inorganic materials 0.000 title description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- -1 2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl Chemical group 0.000 description 7
- 229920003109 sodium starch glycolate Polymers 0.000 description 7
- 229940079832 sodium starch glycolate Drugs 0.000 description 7
- 239000008109 sodium starch glycolate Substances 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014126338A JP6210640B2 (ja) | 2014-06-19 | 2014-06-19 | ホリナートカルシウム含有錠 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014126338A JP6210640B2 (ja) | 2014-06-19 | 2014-06-19 | ホリナートカルシウム含有錠 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017172675A Division JP2017210493A (ja) | 2017-09-08 | 2017-09-08 | ホリナートカルシウム含有錠 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016003224A JP2016003224A (ja) | 2016-01-12 |
| JP2016003224A5 JP2016003224A5 (enrdf_load_stackoverflow) | 2017-04-20 |
| JP6210640B2 true JP6210640B2 (ja) | 2017-10-11 |
Family
ID=55222771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014126338A Active JP6210640B2 (ja) | 2014-06-19 | 2014-06-19 | ホリナートカルシウム含有錠 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6210640B2 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017210493A (ja) * | 2017-09-08 | 2017-11-30 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6160790B1 (ja) | 2017-03-10 | 2017-07-12 | 富士電機株式会社 | 検出装置、パワーコンディショナ、検出方法、および検出プログラム |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
| ITMI20011337A1 (it) * | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio modificato del principio attivo |
| CA2718918A1 (en) * | 2008-03-25 | 2009-11-26 | Schering Corporation | Methods for treating or preventing colorectal cancer |
| CN101862333B (zh) * | 2009-04-20 | 2013-07-24 | 天津药物研究院 | 左亚叶酸钠稳定的口服制剂及其制备方法 |
-
2014
- 2014-06-19 JP JP2014126338A patent/JP6210640B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017210493A (ja) * | 2017-09-08 | 2017-11-30 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016003224A (ja) | 2016-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022215155B2 (en) | Ribociclib tablet | |
| JP4409630B2 (ja) | 経口投与用固形製剤 | |
| TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
| CN113423390A (zh) | 阿法比星制剂及其制备方法 | |
| EP3793529A1 (en) | Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets | |
| TW201717937A (zh) | 含有芳基烷基胺化合物之醫藥組合物 | |
| JP6210640B2 (ja) | ホリナートカルシウム含有錠 | |
| TW201828928A (zh) | 包含苯并咪唑衍生物的新穎調配物 | |
| JP6320260B2 (ja) | 医薬組成物 | |
| WO2015152680A1 (en) | Granule comprising silodosin, and pharmaceutical composition and formulation comprising same | |
| JP2017210493A (ja) | ホリナートカルシウム含有錠 | |
| JP6440294B2 (ja) | テルミサルタン含有フィルムコーティング錠剤 | |
| JP7066351B2 (ja) | 良好な徐放性を有する、レボドパ含有小型化錠剤 | |
| JP2023143873A (ja) | ミラベグロン含有徐放性錠剤及びその製造方法、並びにミラベグロン含有徐放性錠剤の変色・膨張抑制方法 | |
| JP2019085425A (ja) | ホリナートカルシウム含有錠 | |
| JP2021036003A (ja) | ホリナートカルシウム含有錠 | |
| JP5744412B2 (ja) | フロセミド製剤 | |
| WO2013157584A1 (ja) | カプセル剤 | |
| JP2020196697A (ja) | Ｌ−システイン配合ビタミンｃ高含有圧縮成形製剤 | |
| WO2013124774A1 (en) | Stable dosage forms of imatinib mesylate | |
| CN108653223A (zh) | 一种尼洛替尼片剂组合物 | |
| JP2025073688A (ja) | ボスチニブ医薬製剤 | |
| JP6283314B2 (ja) | アナグリプチン含有固形製剤 | |
| CA3150812A1 (en) | Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170314 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20170314 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20170315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170327 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20170404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170731 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170911 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6210640 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |